Raphael (Raphy) Mayer, Ph.D.
Founder & CEO
Dr. Mayer conceived Smart Assays in 2005 and successfully led its development to a profitable company, which is recognized today as an established and reliable CRO serving a wide range of life science companies from incubator initiatives to publically traded companies.
Before Smart Assays Dr. Mayer was the head of Assay Development Department in Quark Biotechnology Inc ("QBI"), Ness-Ziona. Israel. Prior to QBI Dr. Mayer was a team leader in InSight Ltd., Rehovot, Israel. Dr. Mayer's academic experience includes postdoctoral fellowship at Rockefeller University, New York, NY, where he worked on phytochrome signal transduction using molecular, transgenic and genetic models in Arabidopsis.
Dr. Mayer earned his Ph.D. at the department of Biological Chemistry of The Hebrew University of Jerusalem, where he discovered c-di-GMP and its role in regulation of bacterial biofilm. Dr. Mayer received his M.Sc., in Biochemistry, with distinction, from The Hebrew University of Jerusalem where he studied the regulation of cellulose synthesis by c-di-GMP specific phosphodiesterases. Dr. Mayer is an author and co-author of 20 scientific publications, several of them in highly prestigious journals including Nature and PNAS.
Ronny Peri-Naor, Ph.D
Head of Bio-Analytical Unit and Project Manager
Dr. R. Peri-Naor joined Smart Assays in 2016 as a project manager and during 2018 established and became the head of the bio-analytical unit. Dr Peri-Naor is a highly qualified biochemist and bio-analytical researcher with 15 years of academic and industrial professional experience.
Dr. Peri-Naor earned her Ph.D. in the field of bio-organic chemistry in the department of Organic Chemistry of the Weizmann institute of Science. During her Ph.D. she synthesized oligonucleotides-based nano-structures and studied their interactions with proteins and the ability to utilize them for bio-assays development. Dr. Peri-Naor received her B.Sc. and M.Sc., in Biotechnology engineering from Ben-Gurion University. During her masters research in the field of molecular nutrition, she discovered the molecular mechanism by which unsaturated fatty-acids control the expression of the pancreatic lipase. Dr. Peri-Naor is the author and co-author of six scientific publications.
Veatriki Fraggi Rankis, M.Sc.
Mrs F. Rankis Joined Smart Assays in 2011 as a project manager and head of QA. Mrs. Rankis is a highly qualified molecular biologist with 23 years of academic and industrial professional experience. She is a graduate of Tel Aviv University.
Mrs. Rankis received her M.Sc., in Biochemistry, from The Hebrew University of Jerusalem where she studied the expression pattern of osteocalcin in neural crest cells in chick embryos.
Before joining Smart Assays she was a researcher at Quark Pharmaceuticals, Inc. for 9 years. During her career she has gained experience in a broad range of molecular biology and histology techniques.
As head of QA in Smart Assays, she participated in an official ISO 9001 course of the Standards Institution of Israel (SII) and has subsequently implemented the ISO9001:2015 in the company.
Anat Geiger-Maor, Ph.D.
Dr. Geiger-Maor joined Smart Assays in 2020 as a researcher and is now a project manager.
Dr. Geiger-Maor a highly qualified immunologist.
Dr. Geiger-Maor received her M.Sc. and PhD in immunology, from The Hebrew University where she studied the response of the immune system to a non-lethal stress on somatic cells.
Before joining Smart Assays, she worked at IBC LTD as an R&D researcher. During her career, Dr. Geiger-Maor has gained experience in a broad range of techniques including in-vitro assays, cell-based assays, proteome analysis, flow cytometry and microscopy imaging.
Alexander (Sasha) Faerman, Ph.D.
Dr. Faerman is a highly qualified cell biologist and histologist with 33 years of academic and industrial professional experience in studying gene expression at the cellular and tissue levels. Scientific areas of his expertise range from developmental biology to molecular human pathology
and preclinical disease models.
Dr. Faerman heads the Histopathology unit since joining Smart Assays in 2011 and as of July 2019, he began working for 'Merck Israel', and now serves as Histopathology consultant at Smart Assays.
Dr. Faerman served for 4 years as the Senior Director of the In Situ Hybridization Unit in Rosetta Genomics. Before that he served as the Head of the Histopathology and Hybridoma Unit at QBI.
His academic experience includes working as the investigator (equivalent to Associate Professor) in the Institute of Animal Science, Volcani Center (1990-1997).
Dr. Faerman earned his Ph.D. in cell biology from the USSR Academy of Medical Sciences for the discovery and studies of the specific surface antigen of vascular smooth muscle cells. He received his MSc. degree (with distinction) in cytology and histology from the Moscow State University. Dr. Faerman is the author and co-author of more than 40 scientific publications and patents.
Micha Gladnikoff, Ph.D.
Dr. Gladnikoff joined Smart Assays in 2018 as a project manager. Dr. Gladnikoff is a highly qualified biochemist with more than 20 years of academic and industrial professional experience.
Dr.Gladnikoff received his M.Sc., in Chemical Engineering, from The Royal Institute of Technology in Stockholm and his PhD from the Weizmann Institute in Rehovot where he studied the biophysical mechanism driving budding of HIV-1 virus particles.
Before joining Smart Assays he worked at Glusense LTD as a Project Manager for 7 on the development of an implantable glucose monitor. During his career, Dr. Gladnikoff has gained experience in a broad range of techniques including the development of in-vitro assays, cell-based assays, analytical chemistry, and molecular biology.